Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here ...

Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...

Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...

Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...

The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with ...

Fintel reports that on November 18, 2024, Needham downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.

UCB and Biogen (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, or DZP, a novel Fc-free anti-CD40L drug candidate, demonstrating significant ...

The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign ...